IASLC胸膜间皮瘤分期项目:常见分子改变与PD-L1表达对总生存的影响
本研究基于IASLC第九版分期数据库的三机构队列,评估胸膜间皮瘤常见分子改变与PD-L1表达的预后关联。BAP1改变与更好OS相关,CDKN2A、NF2、TP53改变与更差OS相关,PD-L1表达与OS无关。基因组改变可提供超越解剖TNM和临床病理特征的额外预后信息。
要点
- BAP1改变(NGS或IHC表达缺失)与胸膜间皮瘤更好OS独立相关。
- CDKN2A、NF2、TP53致病性改变与更差OS独立相关。
- PD-L1表达(≥1%肿瘤细胞膜染色)与OS无显著关联。
核心结论
- 在胸膜间皮瘤大样本队列中,CDKN2A、NF2、TP53改变与更差OS相关,BAP1改变与更好预后相关,且独立于临床变量和组织学。
- 建模提示基因组改变可提供超越解剖TNM和临床病理特征的额外预后信息。
研究设计与样本
- 来自IASLC第九版分期项目的三机构队列回顾性研究,作为指导未来数据收集的试点研究。
- 生物标志物数据包括PD-L1和BAP1免疫组化,以及二代测序揭示的致病性体细胞基因组改变。
- OS采用Kaplan-Meier法计算,组间比较采用Cox比例风险回归,模型比较采用伪R2和Harrell C统计量。
主要发现
- BAP1致病性改变最常见(55.0%,143/260),其次为CDKN2A(36.2%,94/260)、NF2(23.8%,62/260)和TP53(18.1%,47/260)。
- BAP1免疫组化表达缺失在452例中检出260例(57.5%)。
- PD-L1表达阳性(≥1%肿瘤细胞膜染色)在200例中检出89例(44.5%)。
- 单因素分析中,CDKN2A、NF2、TP53致病性改变与更差OS相关(p ≤ 0.001);BAP1改变和表达缺失与更好OS相关(p = 0.004和p < 0.001);PD-L1表达与OS无关(p = 0.645)。
- 多因素分析证实OS关联(风险比:CDKN2A 2.12;NF2 1.65;TP53 1.74;BAP1 NGS 0.58;BAP1 IHC 0.58)。
关键数值与推荐
- 临床协变量模型优于单纯分子改变模型(C统计量0.67 vs 0.65;R2 25.3 vs 20.8)。
- 包含BAP1改变加CDKN2A、NF2、TP53中任一致病性改变及临床协变量的模型预测生存最佳(C统计量0.70;R2 37.0)。
临床怎么用
- 胸膜间皮瘤患者可考虑检测BAP1、CDKN2A、NF2、TP53改变以辅助预后分层。
- PD-L1表达不宜单独用于胸膜间皮瘤预后判断。
- 基因组改变联合临床病理特征可优化生存预测模型。
局限性
- 研究为三机构队列的试点研究,样本量有限。
- PD-L1和BAP1 IHC及NGS检测的可评估病例数不一致(如PD-L1仅200例)。
- 回顾性设计,分子检测方法及cutoff可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There is currently limited information on the prognostic association of molecular aberrations in pleural mesothelioma. We evaluated the impact of common molecular alterations on overall survival (OS) in a three-institution cohort from the International Association for the Study of Lung Cancer Ninth Edition Staging Project as a pilot study to guide future data collection. METHODS: Biomarker data included programmed death-ligand 1 (PD-L1) and BAP1 immunohistochemistry (IHC), and somatic genomic aberrations with putative functional impact (pathogenic) revealed by next-generation sequencing. OS was calculated by the Kaplan-Meier method and compared between groups by Cox proportional hazard regression. Models were compared using pseudo-R2 and Harrell's C-statistic. RESULTS: Pathogenic alterations in BAP1 were most common (55.0%, 143/260), followed by CDKN2A (36.2%, 94/260), NF2 (23.8%, 62/260), and TP53 (18.1%, 47/260). Loss of BAP1 expression by IHC was detected in 260 of 452 cases (57.5%). PD-L1 expression was positive (≥1% of tumor cells with membranous staining) in 89 of 200 cases (44.5%). On univariate analysis, pathogenic alterations in CDKN2A, NF2, and TP53 were associated with worse OS (p ≤ 0.001); BAP1 alterations and loss of expression were associated with better OS (p = 0.004 and p < 0.001, respectively); and PD-L1 expression was not associated with OS (p = 0.645). Multivariable analyses confirmed OS associations (hazard ratios: CDKN2A, 2.12; NF2, 1.65; TP53, 1.74; BAP1 next-generation sequencing, 0.58; BAP1 IHC, 0.58). Although clinical covariates performed better than molecular alterations alone (C-statistic: 0.67 versus 0.65; R2: 25.3 versus 20.8), a model including BAP1 alterations plus any pathogenic alteration in CDKN2A, NF2, and TP53, along with clinical covariates, best predicted survival (C-statistic: 0.70; R2: 37.0). CONCLUSION: In this large pleural mesothelioma cohort, CDKN2A, NF2, and TP53 alterations were associated with worse OS, whereas BAP1 alterations were associated with better prognosis, independent of clinical variables and histology. Modeling suggests that genomic alterations provide additional prognostic information beyond anatomic TNM and clinicopathologic features.
引用
- Yang SR, Tjota MY, Goren E, et al. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and Programmed Death-Ligand 1 Expression on Overall Survival in a Select Cohort From the International Association for the Study of Lung Cancer Ninth Edition Staging Database. J Thorac Oncol. 2026. PMID: 41833817. doi:10.1016/j.jtho.2026.103681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。